Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTIGA vs FINTEPLA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.
Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.
Adjunctive therapy for partial-onset seizures in adults
Treatment of seizures associated with Dravet syndrome in patients aged 2 years and older,Treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older
100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.
0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.
Terminal elimination half-life is approximately 13-16 hours in healthy individuals, allowing twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged (up to 30 hours).
Terminal elimination half-life approximately 9 hours in adults; at steady state, accumulation minimal with twice-daily dosing.
Primarily glucuronidation by UGT1A9 and UGT2B7; minor CYP2E1 involvement.
Fenfluramine is primarily metabolized by CYP1A2, CYP2B6, and CYP2D6 to its active metabolite norfenfluramine. Norfenfluramine is further metabolized by CYP2D6 and other enzymes.
Renal excretion accounts for approximately 25-30% of the administered dose as unchanged drug; the remainder is eliminated as metabolites via the biliary/fecal route (up to 70%) and further metabolized. Total recovery in urine and feces is >90%, with fecal excretion being the major route.
Renal: 65% as unchanged drug; Fecal: 29% primarily as metabolites; Biliary: negligible.
Approximately 40% bound to albumin, mainly to albumin with minor binding to alpha-1-acid glycoprotein.
Approximately 55% bound to plasma proteins, primarily albumin.
Volume of distribution is approximately 0.7 L/kg, indicating distribution into total body water, and is consistent with low tissue binding.
Apparent volume of distribution (Vd/F) approximately 2.5–3.5 L/kg, suggesting extensive extravascular distribution.
Oral bioavailability is approximately 90% (due to high absorption with minimal first-pass effect).
Oral bioavailability approximately 80% (relatively high first-pass metabolism: moderate).
For Cr Cl 30-79 m L/min: 50 mg once daily for 1 week, then 100 mg twice daily; for Cr Cl 15-29 m L/min: 50 mg once daily for 1 week, then 50 mg twice daily; for Cr Cl <15 m L/min or hemodialysis: 50 mg once daily with post-dialysis supplementation of 50 mg.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease.
Child-Pugh A: no adjustment; Child-Pugh B: 50 mg once daily for 1 week, then 100 mg twice daily; Child-Pugh C: not recommended.
Mild hepatic impairment (Child-Pugh A): maximum dose 11 mg/day. Moderate to severe (Child-Pugh B or C): not recommended.
For children ≥4 years with partial-onset seizures: 1.5 mg/kg/day (maximum 50 mg/day) orally once daily for 1 week, then increase to 3 mg/kg/day (or 100 mg/day) in 2 divided doses for week 2, followed by 4.5 mg/kg/day (or 150 mg/day) in 2 divided doses for week 3, then maintenance of 6 mg/kg/day (or 200 mg/day) in 2 divided doses.
For patients weighing 10-50 kg: initial 0.05 mg/kg twice daily; titrated to 0.1 mg/kg twice daily (target), may increase to 0.2 mg/kg twice daily (max). For patients weighing ≥50 kg: same as adult dosing (max 16 mg/day). Not established for weight <10 kg.
Start at 50 mg once daily for 1 week, then increase to 50 mg twice daily; consider lower doses due to age-related renal impairment; monitor renal function.
No specific dose adjustment; start at low end of dosing range due to greater frequency of decreased hepatic/renal function and concomitant disease.
None.
Valvular heart disease and pulmonary arterial hypertension: FINTEPLA is associated with valvular heart disease (e.g., mitral and aortic regurgitation) and pulmonary arterial hypertension. Patients must undergo echocardiography before starting treatment, at 3 months, and every 6-12 months thereafter.
Neuropsychiatric symptoms (hallucinations, confusion, psychosis),Increased risk of suicidal thoughts/behavior,QT prolongation (dose-dependent),Urinary retention,PR interval prolongation,Hepatotoxicity
Valvular heart disease and pulmonary arterial hypertension: monitor with echocardiography,Increased intraocular pressure: caution in patients with glaucoma,Suicidal thoughts and behavior: monitor for worsening depression and suicidality,Dizziness, somnolence, and fatigue: may impair ability to drive or operate machinery,Decreased appetite and weight loss: monitor weight, especially in pediatric patients,Potential for abuse and dependence: controlled substance (Schedule IV)
Hypersensitivity to ezogabine or any component,Concurrent use with other potassium channel openers (e.g., retigabine),Severe hepatic impairment (Child-Pugh C)
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuation of an MAOI,Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs) due to risk of serotonin syndrome,Hypersensitivity to fenfluramine or any component of the formulation
No significant food interactions reported. Take with or without food. Avoid alcohol and grapefruit juice as they may exacerbate CNS effects or affect metabolism.
Avoid grapefruit and grapefruit juice as they are CYP1A2 inhibitors and may increase fenfluramine exposure. No other significant food interactions reported.
POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester: potential for major malformations, but data insufficient. Second and third trimesters: risk of fetal toxicity and neonatal withdrawal. Should only be used if benefit outweighs risk.
FINTEPLA (fenfluramine) is associated with an increased risk of congenital malformations, particularly cardiac and neural tube defects, when used during the first trimester. In animal studies, fenfluramine caused embryofetal mortality and structural abnormalities at clinically relevant doses. During the second and third trimesters, exposure may lead to fetal growth restriction and neurodevelopmental effects. Use during pregnancy is contraindicated unless no safer alternative exists.
No data on excretion in human milk; M/P ratio unknown. Risk of infant sedation, poor feeding, and withdrawal. Caution advised; consider alternative therapies or discontinue breastfeeding.
Fenfluramine is excreted into human breast milk; the milk-to-plasma (M/P) ratio is approximately 0.5. Based on limited data, the relative infant dose is estimated to be <10% of the maternal weight-adjusted dose. However, prolonged exposure may cause adverse effects in the infant (e.g., irritability, feeding difficulties). Breastfeeding is not recommended during FINTEPLA therapy due to potential for serious adverse reactions.
Pregnancy can decrease ezogabine exposure due to increased clearance and volume of distribution; dose adjustments may be necessary to maintain efficacy. Monitor serum concentrations and clinical response, adjusting dose as needed. Postpartum, monitor for toxicity due to rapid clearance normalization and reduce dose accordingly.
No specific dose adjustments are recommended for pregnancy due to lack of pharmacokinetic studies. However, physiological changes in pregnancy (e.g., increased volume of distribution, altered metabolism) may necessitate therapeutic drug monitoring and dose titration. Use lowest effective dose and consider alternative agents if possible.
Potiga (ezogabine/retigabine) is a neuronal potassium channel opener indicated as adjunctive treatment for partial-onset seizures. Requires ophthalmic monitoring due to risk of retinal pigment changes (blue-gray discoloration) and potential visual field defects. Urothelial effects (urinary retention, dysuria) are common; assess baseline renal function. QT prolongation possible; avoid with other QT-prolonging drugs. Titrate slowly to minimize CNS effects (dizziness, somnolence, ataxia).
FINTEPLA (fenfluramine) is indicated for seizures associated with Dravet syndrome. Monitor for valvular heart disease and pulmonary arterial hypertension due to serotonergic effects; obtain baseline and periodic echocardiograms. Titrate slowly to minimize appetite suppression and weight loss. Avoid concurrent use with monoamine oxidase inhibitors (MAOIs) or other serotonergic drugs due to risk of serotonin syndrome. Dose adjustment required in hepatic impairment.
Take exactly as prescribed; do not abruptly stop therapy.,May cause dizziness or drowsiness; avoid driving until effects known.,Report any vision changes, eye pain, or blue-gray discoloration of skin/nails/retina.,Report difficulty urinating or blood in urine immediately.,Avoid alcohol and other CNS depressants.,Use effective contraception if applicable (can reduce hormonal contraceptive efficacy).,Store at room temperature (68-77°F) in original container.,Do not double dose if missed; contact doctor for missed dose instructions.
Take exactly as prescribed; do not stop abruptly as withdrawal may increase seizure frequency.,Common side effects include decreased appetite, weight loss, diarrhea, and fatigue.,Report any signs of heart problems such as shortness of breath, chest pain, or swelling of ankles.,Avoid grapefruit and grapefruit juice during treatment as it may increase drug levels.,Women of childbearing potential should use effective contraception due to potential fetal harm.,Do not drive or operate heavy machinery until you know how the medication affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTIGA vs FINTEPLA, answered by our medical review team.
POTIGA is a Antiepileptic that works by Selective neuronal potassium channel opener; activates Kv7 channels (KCNQ) to stabilize neuronal membranes and reduce excitability.. FINTEPLA is a Antiepileptic that works by Fenfluramine (FINTEPLA) is a serotonin-releasing agent and serotonin receptor agonist, primarily at 5-HT2 receptors. It also acts as a sigma-1 receptor agonist and modulates GABAergic and glutamatergic transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTIGA and FINTEPLA depend on the specific clinical indication. These are both Antiepileptic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTIGA is: 100 mg orally once daily for 1 week, then increase by 50-100 mg/day at weekly intervals to 300-400 mg/day in 2 divided doses; maximum 400 mg/day.. The standard adult dose of FINTEPLA is: 0.1-0.2 mg/kg twice daily (oral), with a maximum of 16 mg/day for patients weighing ≥50 kg; for patients <50 kg, maximum 8 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTIGA and FINTEPLA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTIGA is classified as Category C. POTIGA (ezogabine) is classified as Pregnancy Category C. Limited human data; animal studies show fetal adverse effects at doses similar to human therapeutic doses. First trimester. FINTEPLA is classified as Category C. FINTEPLA (fenfluramine) is associated with an increased risk of congenital malformations, particularly cardiac and neural tube defects, when used during the first trimester. In ani. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.